- Myocardia, part of the Bristol Myers Squibb now (NYSE:BMY), ended agreement Fulcrum signed in July 2020 to work with therapeutics (Nasdaq:Support) to develop target treatment for the treatment of genetic cardiomyopathic.
- This termination It comes into force on June 26.
- Bottom
